LAS 20
Alternative Names: LAS 20; LAS-20×Latest Information Update: 28 Nov 2024
Price :
$50 *
At a glance
- Originator Lassogen
- Class Antineoplastics; Immunotherapies; Peptides
- Mechanism of Action CCR4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Nov 2024 No recent reports of development identified for research development in Cancer in USA
- 17 Mar 2021 LAS 20 is available for licensing as of 17 Mar 2021. http://www.lassogen.com/contact
- 14 Oct 2020 Early research in Cancer in USA (unspecified route) before October 2020 (Lassogen website, October 2020)